At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
Orthogonal is a Socially Conscious Holding Company. As such, we only invest in co...
Orthogonal is a Socially Conscious Holding Comp...
SINTX Technologies is an OEM ceramics company that develops and commercializes sil...
SINTX Technologies is an OEM ceramics company t...
Robovet Corporation has developed a new MR imaging technology that can also help t...
Robovet Corporation has developed a new MR imag...
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.